Market Segmentation:
- By Product Type
- Vector-based CRISPR products
- DNA-free CRISPR products
- Gene drive CRISPR products
- Others (Ribonucleoprotein complexes, plasmid vectors)
- By Application
- Biomedical applications
- Agricultural applications
- Industrial applications
- Basic research
- Others (Diagnostics, gene therapy)
- By End-User
- Pharmaceutical and biopharmaceutical companies
- Academic and government research institutes
- Contract research organizations (CROs)
- Biotechnology companies
- Others (Agriculture companies, food ingredient manufacturers)
- By Delivery Mode
- Ex vivo
- In vivo
- Others (In vitro)
- By Technology
- CRISPR/Cas9
- CRISPR/Cpf1 (Cas12a)
- Other CRISPR systems (CRISPRi, CRISPRa, CRISPRd)
- By Service Type
- Gene engineering design
- Genomic screening
- Other services (Gene library construction, cell line engineering)
- By Regions
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the CRISPR Gene Editing industry is USD 1.2 billion.
Increasing prevalence of genetic disorders, rising demand for personalized medicine, advancements in gene sequencing technologies, growing research and development activities, and expanding applications in various fields.
Ethical and regulatory concerns, high cost of CRISPR therapies, technical challenges in gene editing, limited expertise and infrastructure, and potential off-target effects.
The leading component segment in the CRISPR Gene Editing Market is the vector-based CRISPR products segment, widely used in gene therapy and research applications.
CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Caribou Biosciences, Vertex Pharmaceuticals, Sangamo Therapeutics, Precision BioSciences, Casebia Therapeutics, Beam Therapeutics, and Excision BioTherapeutics.
The CRISPR Gene Editing Market is expected to grow at a CAGR of 32.1% during the forecast period, and North America is expected to lead the market.
Increasing prevalence of genetic disorders, rising demand for personalized medicine, advancements in gene sequencing technologies, growing research and development activities, expanding applications in various fields, and increasing investments and funding.